ASX - Delayed Quote AUD

Healius Limited (HLS.AX)

Compare
1.3850
-0.0250
(-1.77%)
At close: 4:10:38 PM GMT+11
Loading Chart for HLS.AX
  • Previous Close 1.4100
  • Open 1.3800
  • Bid 1.3850 x --
  • Ask 1.3900 x --
  • Day's Range 1.3650 - 1.4100
  • 52 Week Range 1.0800 - 1.8600
  • Volume 1,263,050
  • Avg. Volume 1,808,814
  • Market Cap (intraday) 1.006B
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9600
  • Earnings Date Feb 20, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 7, 2022
  • 1y Target Est 1.35

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories, medical centers, patient collection centers, and community imaging centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

www.healius.com.au

4,329

Full Time Employees

June 30

Fiscal Year Ends

Recent News: HLS.AX

View More

Performance Overview: HLS.AX

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

HLS.AX
1.09%
S&P/ASX 200 [XJO] (^AXJO)
6.02%

1-Year Return

HLS.AX
6.54%
S&P/ASX 200 [XJO] (^AXJO)
1.36%

3-Year Return

HLS.AX
65.58%
S&P/ASX 200 [XJO] (^AXJO)
2.05%

5-Year Return

HLS.AX
21.80%
S&P/ASX 200 [XJO] (^AXJO)
51.31%

Compare To: HLS.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HLS.AX

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    1.01B

  • Enterprise Value

    2.29B

  • Trailing P/E

    --

  • Forward P/E

    125.00

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.52

  • Price/Book (mrq)

    0.98

  • Enterprise Value/Revenue

    1.31

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.27%

  • Return on Assets (ttm)

    1.34%

  • Return on Equity (ttm)

    -3.08%

  • Revenue (ttm)

    1.79B

  • Net Income Avi to Common (ttm)

    -32M

  • Diluted EPS (ttm)

    -0.9600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    115.4M

  • Total Debt/Equity (mrq)

    136.23%

  • Levered Free Cash Flow (ttm)

    -195.19M

Research Analysis: HLS.AX

View More

Company Insights: HLS.AX

Research Reports: HLS.AX

View More

People Also Watch